По состоянию на июнь 2016 года только в Американской национальной медицинской библиотеке 180 выдающихся ученых из 8 стран повторно опубликовали 73 основные научные работы по GcMAF. С ними можно ознакомиться в правительственной системе США Pubmed.

Еще столько же работ опубликовано в других странах, так что во всем мире в общей сложности будет опубликовано около 140 научных работ 300 ученых.

В компании Immuno Biotech Ltd мы написали 33 исследовательские работы по GcMAF с 2012 года. Все они прошли экспертную оценку и опубликованы в престижных научных журналах или на конференциях по иммунологии. И они также размещены на этом сайте. На Pubmed есть только половина.

Вот список в Медицинской библиотеке США, http://www.ncbi.nlm.nih.gov/pubmed

при поиске по:

GcMAF OR DBPMAF OR » vitamin D binding protein» AND «macrophage activating factor»

1: Hamilton G, Rath B, Klameth L, Hochmair MJ. Small cell lung cancer:
Recruitment of macrophages by circulating tumor cells. Oncoimmunology. 2015 Oct
29;5(3):e1093277. eCollection 2016 Mar. PubMed PMID: 27141354; PubMed Central
PMCID: PMC4839345.

2: Delanghe JR, Speeckaert R, Speeckaert MM. Behind the scenes of vitamin D
binding protein: more than vitamin D binding. Best Pract Res Clin Endocrinol
Metab. 2015 Oct;29(5):773-86. doi: 10.1016/j.beem.2015.06.006. Epub 2015 Jul 2.
Review. PubMed PMID: 26522461.

3: Inui T, Kubo K, Kuchiike D, Uto Y, Nishikata T, Sakamoto N, Mette M. Oral
Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue
Syndrome: Three Case Reports. Anticancer Res. 2015 Aug;35(8):4545-9. PubMed PMID:
26168499.

4: Uto Y, Kawai T, Sasaki T, Hamada K, Yamada H, Kuchiike D, Kubo K, Inui T,
Mette M, Tokunaga K, Hayakawa A, Go A, Oosaki T. Degalactosylated/Desialylated
Bovine Colostrum Induces Macrophage Phagocytic Activity Independently of
Inflammatory Cytokine Production. Anticancer Res. 2015 Aug;35(8):4487-92. PubMed
PMID: 26168491.

5: Branca JJ, Morucci G, Malentacchi F, Gelmini S, Ruggiero M, Pacini S. Effects
of oxaliplatin and oleic acid Gc-protein-derived macrophage-activating factor on
murine and human microglia. J Neurosci Res. 2015 Sep;93(9):1364-77. doi:
10.1002/jnr.23588. Epub 2015 Mar 18. PubMed PMID: 25782915.

6: Morucci G, Branca JJ, Gulisano M, Ruggiero M, Paternostro F, Pacini A, Di
Cesare Mannelli L, Pacini S. Gc-protein-derived macrophage activating factor
counteracts the neuronal damage induced by oxaliplatin. Anticancer Drugs. 2015
Feb;26(2):197-209. doi: 10.1097/CAD.0000000000000177. PubMed PMID: 25304987.

7: Immunotherapy of metastatic colorectal cancer with vitamin D-binding
protein-derived macrophage-activating factor, GcMAF. Cancer Immunol
Immunother. 2014 Dec;63(12):1349.

8: ‘Immunotherapy of metastatic breast cancer patients with vitamin D-binding
protein-derived macrophage activating factor (GcMAF)’ by Yamamoto, N., Suyama,
H., Yamamoto, N. and Ushijima, N. Int J Cancer. 2014 Sep 15;135(6):1509. PubMed
PMID: 25180398.

9: Inui T, Makita K, Miura H, Matsuda A, Kuchiike D, Kubo K, Mette M, Uto Y,
Nishikata T, Hori H, Sakamoto N. Case report: A breast cancer patient treated
with GcMAF, sonodynamic therapy and hormone therapy. Anticancer Res. 2014
Aug;34(8):4589-93. Erratum in: Anticancer Res. 2015 Apr;35(4):2477. PubMed PMID:
25075104.

10: Ishikawa M, Inoue T, Inui T, Kuchiike D, Kubo K, Uto Y, Nishikata T. A novel
assay system for macrophage-activating factor activity using a human U937 cell
line. Anticancer Res. 2014 Aug;34(8):4577-81. PubMed PMID: 25075102.

11: Ruggiero M, Ward E, Smith R, Branca JJ, Noakes D, Morucci G, Taubmann M,
Thyer L, Pacini S. Oleic Acid, deglycosylated vitamin D-binding protein, nitric
oxide: a molecular triad made lethal to cancer. Anticancer Res. 2014
Jul;34(7):3569-78. PubMed PMID: 24982371.

12: Siniscalco D, Bradstreet JJ, Cirillo A, Antonucci N. The in vitro GcMAF
effects on endocannabinoid system transcriptionomics, receptor formation, and
cell activity of autism-derived macrophages. J Neuroinflammation. 2014 Apr
17;11:78. doi: 10.1186/1742-2094-11-78. PubMed PMID: 24739187; PubMed Central
PMCID: PMC3996516.

13: Ikeda T, Kasai M, Tatsukawa E, Kamitakahara M, Shibata Y, Yokoi T, Nemoto TK,
Ioku K. A bone substitute with high affinity for vitamin D-binding
protein–relationship with niche of osteoclasts. J Cell Mol Med. 2014
Jan;18(1):170-80. doi: 10.1111/jcmm.12180. Epub 2013 Nov 28. PubMed PMID:
24286277; PubMed Central PMCID: PMC3916128.

14: Thyer L, Ward E, Smith R, Branca JJ, Morucci G, Gulisano M, Noakes D,
Eslinger R, Pacini S. GC protein-derived macrophage-activating factor decreases
α-N-acetylgalactosaminidase levels in advanced cancer patients. Oncoimmunology.
2013 Aug 1;2(8):e25769. Epub 2013 Jul 29. PubMed PMID: 24179708; PubMed Central
PMCID: PMC3812199.

15: Sayegh L, Fuleihan Gel-H, Nassar AH. Vitamin D in endometriosis: a causative
or confounding factor? Metabolism. 2014 Jan;63(1):32-41. doi:
10.1016/j.metabol.2013.09.012. Epub 2013 Oct 14. Review. PubMed PMID: 24135500.

16: Thyer L, Ward E, Smith R, Fiore MG, Magherini S, Branca JJ, Morucci G,
Gulisano M, Ruggiero M, Pacini S. A novel role for a major component of the
vitamin D axis: vitamin D binding protein-derived macrophage activating factor
induces human breast cancer cell apoptosis through stimulation of macrophages.
Nutrients. 2013 Jul 8;5(7):2577-89. doi: 10.3390/nu5072577. PubMed PMID:
23857228; PubMed Central PMCID: PMC3738989.

17: Inui T, Kuchiike D, Kubo K, Mette M, Uto Y, Hori H, Sakamoto N. Clinical
experience of integrative cancer immunotherapy with GcMAF. Anticancer Res. 2013
Jul;33(7):2917-9. PubMed PMID: 23780980.

18: Hirota K, Nakagawa Y, Takeuchi R, Uto Y, Hori H, Onizuka S, Terada H.
Antitumor effect of degalactosylated gc-globulin on orthotopic grafted lung
cancer in mice. Anticancer Res. 2013 Jul;33(7):2911-5. PubMed PMID: 23780979.

19: Kuchiike D, Uto Y, Mukai H, Ishiyama N, Abe C, Tanaka D, Kawai T, Kubo K,
Mette M, Inui T, Endo Y, Hori H. Degalactosylated/desialylated human serum
containing GcMAF induces macrophage phagocytic activity and in vivo antitumor
activity. Anticancer Res. 2013 Jul;33(7):2881-5. PubMed PMID: 23780974.

20: Toyohara Y, Hashitani S, Kishimoto H, Noguchi K, Yamamoto N, Urade M.
Inhibitory effect of vitamin D-binding protein-derived macrophage activating
factor on DMBA-induced hamster cheek pouch carcinogenesis and its derived
carcinoma cell line. Oncol Lett. 2011 Jul;2(4):685-691. Epub 2011 May 13. PubMed
PMID: 22848250; PubMed Central PMCID: PMC3406437.

21: Bellone M, Rigamonti N. Vitamin D-binding protein-derived
macrophage-activating factor, GcMAF, and prostate cancer. Cancer Immunol
Immunother. 2012 Dec;61(12):2377-8. doi: 10.1007/s00262-012-1310-9. Epub 2012 Jun
28. PubMed PMID: 22740161.

22: Uto Y, Yamamoto S, Mukai H, Ishiyama N, Takeuchi R, Nakagawa Y, Hirota K,
Terada H, Onizuka S, Hori H. β-Galactosidase treatment is a common first-stage
modification of the three major subtypes of Gc protein to GcMAF. Anticancer Res.
2012 Jun;32(6):2359-64. PubMed PMID: 22641675.

23: Pacini S, Punzi T, Morucci G, Gulisano M, Ruggiero M. Effects of vitamin
D-binding protein-derived macrophage-activating factor on human breast cancer
cells. Anticancer Res. 2012 Jan;32(1):45-52. PubMed PMID: 22213287.

24: Pacini S, Morucci G, Punzi T, Gulisano M, Ruggiero M, Amato M, Aterini S.
Effect of paricalcitol and GcMAF on angiogenesis and human peripheral blood
mononuclear cell proliferation and signaling. J Nephrol. 2012
Jul-Aug;25(4):577-81. doi: 10.5301/jn.5000035. PubMed PMID: 21956771.

25: Uto Y, Yamamoto S, Takeuchi R, Nakagawa Y, Hirota K, Terada H, Onizuka S,
Nakata E, Hori H. Effect of the Gc-derived macrophage-activating factor precursor
(preGcMAF) on phagocytic activation of mouse peritoneal macrophages. Anticancer
Res. 2011 Jul;31(7):2489-92. PubMed PMID: 21873164.

26: Debruyne E, Speeckaert M, Weygaerde YV, Delanghe J. Phenotype of Gc-globulin
influences the macrophage activating factor (MAF) levels in serum. Clin Chem Lab
Med. 2011 Nov;49(11):1855-60. doi: 10.1515/CCLM.2011.676. Epub 2011 Aug 23.
PubMed PMID: 21859424.

27: Pacini S, Morucci G, Punzi T, Gulisano M, Ruggiero M. Gc protein-derived
macrophage-activating factor (GcMAF) stimulates cAMP formation in human
mononuclear cells and inhibits angiogenesis in chick embryo chorionallantoic
membrane assay. Cancer Immunol Immunother. 2011 Apr;60(4):479-85. doi:
10.1007/s00262-010-0953-7. Epub 2010 Dec 14. PubMed PMID: 21170647.

28: Faserl K, Golderer G, Kremser L, Lindner H, Sarg B, Wildt L, Seeber B.
Polymorphism in vitamin D-binding protein as a genetic risk factor in the
pathogenesis of endometriosis. J Clin Endocrinol Metab. 2011 Jan;96(1):E233-41.
doi: 10.1210/jc.2010-1532. Epub 2010 Oct 27. PubMed PMID: 20980430.

29: Gregory KJ, Zhao B, Bielenberg DR, Dridi S, Wu J, Jiang W, Huang B,
Pirie-Shepherd S, Fannon M. Vitamin D binding protein-macrophage activating
factor directly inhibits proliferation, migration, and uPAR expression of
prostate cancer cells. PLoS One. 2010 Oct 18;5(10):e13428. doi:
10.1371/journal.pone.0013428. PubMed PMID: 20976141; PubMed Central PMCID:
PMC2956649.

30: Nonaka K, Onizuka S, Ishibashi H, Uto Y, Hori H, Nakayama T, Matsuura N,
Kanematsu T, Fujioka H. Vitamin D binding protein-macrophage activating factor
inhibits HCC in SCID mice. J Surg Res. 2012 Jan;172(1):116-22. doi:
10.1016/j.jss.2010.07.057. Epub 2010 Sep 17. PubMed PMID: 20855083.

31: Ravnsborg T, Olsen DT, Thysen AH, Christiansen M, Houen G, Højrup P. The
glycosylation and characterization of the candidate Gc macrophage activating
factor. Biochim Biophys Acta. 2010 Apr;1804(4):909-17. doi:
10.1016/j.bbapap.2009.12.022. Epub 2010 Jan 13. PubMed PMID: 20079467.

32: Rehder DS, Nelson RW, Borges CR. Glycosylation status of vitamin D binding
protein in cancer patients. Protein Sci. 2009 Oct;18(10):2036-42. doi:
10.1002/pro.214. PubMed PMID: 19642159; PubMed Central PMCID: PMC2786967.

33: Fang Y, van Meurs JB, Arp P, van Leeuwen JP, Hofman A, Pols HA, Uitterlinden
AG. Vitamin D binding protein genotype and osteoporosis. Calcif Tissue Int. 2009
Aug;85(2):85-93. doi: 10.1007/s00223-009-9251-9. Epub 2009 Jun 2. PubMed PMID:
19488670; PubMed Central PMCID: PMC2729412.

34: Yamamoto N, Ushijima N, Koga Y. Immunotherapy of HIV-infected patients with
Gc protein-derived macrophage activating factor (GcMAF). J Med Virol. 2009
Jan;81(1):16-26. doi: 10.1002/jmv.21376.

35: Yamamoto N, Suyama H, Yamamoto N. Immunotherapy for Prostate Cancer with Gc
Protein-Derived Macrophage-Activating Factor, GcMAF. Transl Oncol. 2008
Jul;1(2):65-72. PubMed PMID: 18633461; PubMed Central PMCID: PMC2510818.

36: Spiriti J, Bogani F, van der Vaart A, Ghirlanda G. Modulation of protein
stability by O-glycosylation in a designed Gc-MAF analog. Biophys Chem. 2008
May;134(3):157-67. doi: 10.1016/j.bpc.2008.02.005. Epub 2008 Feb 21. PubMed PMID:
18329161.

37: Yamamoto N, Suyama H, Nakazato H, Yamamoto N, Koga Y. Immunotherapy of
metastatic colorectal cancer with vitamin D-binding protein-derived
macrophage-activating factor, GcMAF. Cancer Immunol Immunother. 2008
Jul;57(7):1007-16. Retraction in: Cancer Immunol Immunother. 2014
Dec;63(12):1349. PubMed PMID: 18058096.

38: Yamamoto N, Suyama H, Yamamoto N, Ushijima N. Immunotherapy of metastatic
breast cancer patients with vitamin D-binding protein-derived macrophage
activating factor (GcMAF). Int J Cancer. 2008 Jan 15;122(2):461-7. Retraction in:
Int J Cancer. 2014 Sep 15;135(6):1509. PubMed PMID: 17935130.

39: Meier U, Gressner O, Lammert F, Gressner AM. Gc-globulin: roles in response
to injury. Clin Chem. 2006 Jul;52(7):1247-53. Epub 2006 May 18. Review. PubMed
PMID: 16709624.

40: Kalkunte S, Brard L, Granai CO, Swamy N. Inhibition of angiogenesis by
vitamin D-binding protein: characterization of anti-endothelial activity of
DBP-maf. Angiogenesis. 2005;8(4):349-60. Epub 2006 Jan 7. PubMed PMID: 16400520.

41: Yamamoto N, Urade M. Pathogenic significance of
alpha-N-acetylgalactosaminidase activity found in the hemagglutinin of influenza
virus. Microbes Infect. 2005 Apr;7(4):674-81. Epub 2005 Mar 22. PubMed PMID:
15848273.

42: Nagasawa H, Sasaki H, Uto Y, Kubo S, Hori H. Association of the macrophage
activating factor (MAF) precursor activity with polymorphism in vitamin D-binding
protein. Anticancer Res. 2004 Sep-Oct;24(5C):3361-6. PubMed PMID: 15515432.

43: Onizuka S, Kawakami S, Taniguchi K, Fujioka H, Miyashita K. Pancreatic
carcinogenesis: apoptosis and angiogenesis. Pancreas. 2004 Apr;28(3):317-9.
PubMed PMID: 15084979.

44: Matsuura T, Uematsu T, Yamaoka M, Furusawa K. Effect of salivary gland
adenocarcinoma cell-derived alpha-N-acetylgalactosaminidase on the bioactivity of
macrophage activating factor. Int J Oncol. 2004 Mar;24(3):521-8. PubMed PMID:
14767536.

45: Schneider GB, Grecco KJ, Safadi FF, Popoff SN. The anabolic effects of
vitamin D-binding protein-macrophage activating factor (DBP-MAF) and a novel
small peptide on bone. Crit Rev Eukaryot Gene Expr. 2003;13(2-4):277-84. PubMed
PMID: 14696974.

46: Mohamad SB, Nagasawa H, Sasaki H, Uto Y, Nakagawa Y, Kawashima K, Hori H. Gc
protein-derived macrophage activating factor (GcMAF): isoelectric focusing
pattern and tumoricidal activity. Anticancer Res. 2003 Nov-Dec;23(6a):4451-7.
PubMed PMID: 14666733.

47: Gumireddy K, Reddy CD, Swamy N. Mitogen-activated protein kinase pathway
mediates DBP-maf-induced apoptosis in RAW 264.7 macrophages. J Cell Biochem. 2003
Sep 1;90(1):87-96. PubMed PMID: 12938159.

48: Kisker O, Onizuka S, Becker CM, Fannon M, Flynn E, D’Amato R, Zetter B,
Folkman J, Ray R, Swamy N, Pirie-Shepherd S. Vitamin D binding protein-macrophage
activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice.
Neoplasia. 2003 Jan-Feb;5(1):32-40. PubMed PMID: 12659668; PubMed Central PMCID:
PMC1502120.

49: Mohamad SB, Nagasawa H, Uto Y, Hori H. Preparation of Gc protein-derived
macrophage activating factor (GcMAF) and its structural characterization and
biological activities. Anticancer Res. 2002 Nov-Dec;22(6C):4297-300. PubMed PMID:
12553073.

50: Kanda S, Mochizuki Y, Miyata Y, Kanetake H, Yamamoto N. Effects of vitamin
D(3)-binding protein-derived macrophage activating factor (GcMAF) on
angiogenesis. J Natl Cancer Inst. 2002 Sep 4;94(17):1311-9. PubMed PMID:
12208896.

51: Swamy N, Ghosh S, Schneider GB, Ray R. Baculovirus-expressed vitamin
D-binding protein-macrophage activating factor (DBP-maf) activates osteoclasts
and binding of 25-hydroxyvitamin D(3) does not influence this activity. J Cell
Biochem. 2001;81(3):535-46. PubMed PMID: 11255236.

52: Kanan RM, Cook DB, Datta HK. Lectin immunoassay for macrophage-activating
factor (Gc-MAF) produced by deglycosylation of Gc-globulin: evidence for
noninducible generation of Gc-MAF. Clin Chem. 2000 Mar;46(3):412-4. PubMed PMID:
10702530.

53: Odgren PR, Popoff SN, Safadi FF, MacKay CA, Mason-Savas A, Seifert MF, Marks
SC Jr. The toothless osteopetrotic rat has a normal vitamin D-binding
protein-macrophage activating factor (DBP-MAF) cascade and chondrodysplasia
resistant to treatments with colony stimulating factor-1 (CSF-1) and/or DBP-MAF.
Bone. 1999 Aug;25(2):175-81. PubMed PMID: 10456382.

54: Koga Y, Naraparaju VR, Yamamoto N. Antitumor effect of vitamin D-binding
protein-derived macrophage activating factor on Ehrlich ascites tumor-bearing
mice. Proc Soc Exp Biol Med. 1999 Jan;220(1):20-6. PubMed PMID: 9893164.

55: Adebanjo OA, Moonga BS, Haddad JG, Huang CL, Zaidi M. A possible new role for
vitamin D-binding protein in osteoclast control: inhibition of extracellular Ca2+
sensing at low physiological concentrations. Biochem Biophys Res Commun. 1998 Aug
28;249(3):668-71. PubMed PMID: 9731194.

56: Yamamoto N, Naraparaju VR. Structurally well-defined macrophage activating
factor derived from vitamin D3-binding protein has a potent adjuvant activity for
immunization. Immunol Cell Biol. 1998 Jun;76(3):237-44. PubMed PMID: 9682967.

57: Yamamoto N, Naraparaju VR. Immunotherapy of BALB/c mice bearing Ehrlich
ascites tumor with vitamin D-binding protein-derived macrophage activating
factor. Cancer Res. 1997 Jun 1;57(11):2187-92. PubMed PMID: 9187119.

58: Yamamoto N, Naraparaju VR, Moore M, Brent LH. Deglycosylation of serum
vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the
plasma of patients with systemic lupus erythematosus. Clin Immunol Immunopathol.
1997 Mar;82(3):290-8. PubMed PMID: 9073553.

59: Yamamoto N, Naraparaju VR, Urade M. Prognostic utility of serum
alpha-N-acetylgalactosaminidase and immunosuppression resulted from
deglycosylation of serum Gc protein in oral cancer patients. Cancer Res. 1997 Jan
15;57(2):295-9. PubMed PMID: 9000571.

60: Korbelik M, Naraparaju VR, Yamamoto N. Macrophage-directed immunotherapy as
adjuvant to photodynamic therapy of cancer. Br J Cancer. 1997;75(2):202-7. PubMed
PMID: 9010027; PubMed Central PMCID: PMC2063270.

61: Benis KA, Schneider GB. The effects of vitamin D binding protein-macrophage
activating factor and colony-stimulating factor-1 on hematopoietic cells in
normal and osteopetrotic rats. Blood. 1996 Oct 15;88(8):2898-905. PubMed PMID:
8874186.

62: Yamamoto N. Structural definition of a potent macrophage activating factor
derived from vitamin D3-binding protein with adjuvant activity for antibody
production. Mol Immunol. 1996 Oct;33(15):1157-64. PubMed PMID: 9070663.

63: Yamamoto N, Naraparaju VR. Role of vitamin D3-binding protein in activation
of mouse macrophages. J Immunol. 1996 Aug 15;157(4):1744-9. PubMed PMID: 8759764.

64: Yamamoto N, Naraparaju VR, Orchard PJ. Defective lymphocyte glycosidases in
the macrophage activation cascade of juvenile osteopetrosis. Blood. 1996 Aug
15;88(4):1473-8. PubMed PMID: 8695868.

65: Yamamoto N, Naraparaju VR. A defect in inducible beta-galactosidase of B
lymphocytes in the osteopetrotic (mi/mi) mouse. Immunology. 1996
Aug;88(4):604-10. PubMed PMID: 8881764; PubMed Central PMCID: PMC1456628.

66: Yamamoto N, Naraparaju VR, Asbell SO. Deglycosylation of serum vitamin
D3-binding protein leads to immunosuppression in cancer patients. Cancer Res.
1996 Jun 15;56(12):2827-31. PubMed PMID: 8665521.

67: Yamamoto N, Naraparaju VR. Vitamin D3-binding protein as a precursor for
macrophage activating factor in the inflammation-primed macrophage activation
cascade in rats. Cell Immunol. 1996 Jun 15;170(2):161-7. PubMed PMID: 8660814.

68: Yamamoto N, Naraparaju VR. A defect in beta-galactosidase of B lymphocytes in
the osteopetrotic (op/op) mouse. Immunol Lett. 1996 Apr;50(1-2):35-40. PubMed
PMID: 8793557.

69: Yamamoto N, Naraparaju VR, Srinivasula SM. Structural modification of serum
vitamin D3-binding protein and immunosuppression in AIDS patients. AIDS Res Hum
Retroviruses. 1995 Nov;11(11):1373-8. PubMed PMID: 8573395.

70: Schneider GB, Benis KA, Flay NW, Ireland RA, Popoff SN. Effects of vitamin D
binding protein-macrophage activating factor (DBP-MAF) infusion on bone
resorption in two osteopetrotic mutations. Bone. 1995 Jun;16(6):657-62. PubMed
PMID: 7669443.

71: Naraparaju VR, Yamamoto N. Roles of beta-galactosidase of B lymphocytes and
sialidase of T lymphocytes in inflammation-primed activation of macrophages.
Immunol Lett. 1994 Dec;43(3):143-8. PubMed PMID: 7721326.

72: Yamamoto N, Willett NP, Lindsay DD. Participation of serum proteins in the
inflammation-primed activation of macrophages. Inflammation. 1994
Jun;18(3):311-22. PubMed PMID: 8088927.

73: Yamamoto N, Lindsay DD, Naraparaju VR, Ireland RA, Popoff SN. A defect in the
inflammation-primed macrophage-activation cascade in osteopetrotic rats. J
Immunol. 1994 May 15;152(10):5100-7. PubMed PMID: 8176226.

74: Yamamoto N, Kumashiro R. Conversion of vitamin D3 binding protein
(group-specific component) to a macrophage activating factor by the stepwise
action of beta-galactosidase of B cells and sialidase of T cells. J Immunol. 1993
Sep 1;151(5):2794-802. PubMed PMID: 8360493.

75: Homma S, Yamamoto M, Yamamoto N. Vitamin D-binding protein (group-specific
component) is the sole serum protein required for macrophage activation after
treatment of peritoneal cells with lysophosphatidylcholine. Immunol Cell Biol.
1993 Aug;71 ( Pt 4):249-57. PubMed PMID: 8225394.

76: Yamamoto N, Homma S, Haddad JG, Kowalski MA. Vitamin D3 binding protein
required for in vitro activation of macrophages after alkylglycerol treatment of
mouse peritoneal cells. Immunology. 1991 Nov;74(3):420-4. PubMed PMID: 1769691;
PubMed Central PMCID: PMC1384634.

77: Yamamoto N, Homma S. Vitamin D3 binding protein (group-specific component) is
a precursor for the macrophage-activating signal factor from
lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci U S A. 1991 Oct
1;88(19):8539-43. PubMed PMID: 1924312; PubMed Central PMCID: PMC52544.

78: Yamamoto N, Homma S, Millman I. Identification of the serum factor required
for in vitro activation of macrophages. Role of vitamin D3-binding protein (group
specific component, Gc) in lysophospholipid activation of mouse peritoneal
macrophages. J Immunol. 1991 Jul 1;147(1):273-80. PubMed PMID: 2051023.